International Business Machines Corporation

Boehringer Ingelheim International Gmbh

Lenovo (singapore) Pte. Ltd.

Novartis Ag

Hydra Biosciences, Inc.

Gilead Sciences, Inc.

Aerie Pharmaceuticals, Inc.

Michael Robert Turner

Richard Bealkowski

Hidenori Takahashi

Lana Louise Smith Keenan

Qiang Zhang

Robert Sibley

Thomas Martin Kirrane, Jr

Steven Richard Brunette

Hossein Razavi

Robert Owen Hughes

John David Ginn

Thierry Bouyssou

Christopher Ronald Sarko

Xinyuan Edward Wu

Michael Jason Burke

Michael Dennis Lowe

Xiang Li

Asitha Abeywardane

Simon Surprenant

Frank Wu

Niklas Heine

Lifen Wu

Roger John Snow

Erick Richard Roush Young

Dirk Gottschling

Ronald John Sorcek

Joseph Michael Young

Matthew Russell Netherton

Anil Kumar Padyana

Anthony S Prokopowicz

Shuang Liang

Sabine K Schlyer

Qing Zhang

Delphine Collin

Qian Zhao

Weimin Liu

Renee M Zindell

Britton Kenneth Corkey

David C Tully

Todd Bosanac

Ralph M Begun

Samuel E Metobo

John W Blackledge, Jr

Daniel Richard Marshall

Naomi S Rajapaksa

Douglas R Geisler

Johanna Csengery

Robert Joseph Moreau

Yipin Lu

Di Wu

Erick Richard Young

Galen Paul Shearn-Nance

Cheng-Kon Shih

Zef Konst

Johanna Bakonyi

Eugene Richard Hickey

Thomas Martin Kirrane

Josep Cors

Sumeet Kochar

Theodore Brian Vojnovich

Alan Richard Tannenbaum

Suresh R Kapadia

Yunlong Zhang

Zhaoming Xiong

Patrick Leo Caporale

Thomas J Clement

Brian Nicholas Cook

Jiang-Ping Wu

Stephen P Thompson

Peichao Lu

Ingo Andreas Mugge

Adam Lee Soderlund

Sonia Rodriguez

Jerry William Pearce

Benjamin Russell Grimes

David J Bradley

John D Huber

Charles David Bauman

Chuk Chui Man

Steven John Taylor

Anjan Saha

Michael J Burke

Jianwen Cui

Martin A Reed

Lana Louise Smith-Keenan

Rhonda Seiber Doane

Paul Nicklin

William K Shetterly

John J D'Ambrose

Doyle Stanfill Cronk

Bradly J Konopik

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Antiviral pyrazolopiridinone compounds

The invention relates to compounds of Formula I:

Compounds and compositions for the treatment of cryptosporidiosis

The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Inhibitors of TRPC6

Antiviral pyrazolopyridinone compounds

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein Rto R, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Rho kinase inhibitors

The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Pteridine derivatives as modulators of ROR gamma

Cajon drum

The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Compounds as modulators of RORC

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Compounds as modulators of ROR&#x3b3;

Cavity drum

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, A, Land B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Inhibitors of leukotriene production

Growing community of inventors

Danbury, CT, United States of America

Michael Robert Turner